|
2010 Research Interest Groups (RIGS) Research Funding Opportunity (click here) Meet the Experts: Videos Special Guidelines and Studies: CMSC News: - March 1, 2010 - Stanford University halts CCSVI treatments after two serious incidents
Researchers at Stanford University have halted treatments for chronic cerebrospinal venous insufficiency (CCSVI) according February's edition of the journal Annals of Neurology. - February 24, 2010 - NORD Applauds NIH and FDA Joint Initiative
The National Organization for Rare Disorders (NORD) today praised the announcement by two of the nation’s leading health-related federal agencies of a new collaborative effort to accelerate the development of innovative medical treatments and more effectively evaluate new products to make them available to the public. - February 8, 2010 - Can DO MS Remembers its Founder
Can Do Multiple Sclerosis founder Jimmie Heuga passed away peacefully Monday, Feb. 8, 2010. Can Do Multiple Sclerosis's board and staff are deeply saddened. Our condolences go to his family and friends. He continues to be an inspiration to all. - January 21, 2010 - New Information about Oral Medication to Treat MS
There is much to be excited about with recent news published January 20, 2010 in the New England Journal of Medicine (http://content.nejm.org/). You will find three articles which detail results from the Phase 3 studies of Novartis' Fingolimod (FTY720) and EMD Serono's Cladribine and an editorial by Dr. William M. Carroll, MB, BS, MD, FRACP. CMSC INForMS (Industry News for MS): - March 9, 2010 - BOTOX® (ONABOTULINUMTOXINA) Receives FDA Approval For Treatment of Upper Limb Spasticity in Adults
- March 1, 2010 - Acorda Therapeutics Announces Availability of AMPYRA (dalfampridine)
- February 26, 2010 - Copaxone 15-Year Study in Multiple Sclerosis Patients Demonstrates Robust Long-Term Efficacy and Safety
- February 19, 2010 - Novartis oral multiple sclerosis development compound Gilenia®* (FTY720) granted US priority review status
- February 16, 2010 - DACLIZUMAB Shows Potential for New Immunoregulatory Approach to Treating Multiple Sclerosis, according to Data Published in the Lancet Neurology
- February 8, 2010 - Active Biotech (SE) - Teva Acquires Marketing Rights For Oral Laquinimod In The Nordic And Baltic Regions
- February 8, 2010 - Multiple Sclerosis Experts Join Biogen Idec's Research and Development Team
- February 5, 2010 - Tysabri (Natalizumab): Risk of developing progressive multifocal leukoencephalopathy (PML) increases with increasing duration of exposure to Tysabri
- February 3, 2010 - Acorda Therapeutics Announces Pricing and Patient Assistance Programs for Ampyra (dalfampridine)
- January 27, 2010 - Biogen Idec Moves Regenerative Medicine Drug into Human Trials
- January 25, 2010 - PROLOR Biotech Reports Positive Results From Comparative Study of Its Longer-Acting Version of Multiple Sclerosis Drug Interferon Beta in Primates
- January 22, 2010 - Acorda Therapeutics Announces FDA Approval of AMPYRA
MS Exchange Issue Slides with Audio Presentation - Fundamentals of MS
Stanley J. Krolczyk DO, RPH - Headache and MS: Learning from Each Other
Daniel M Kantor, MD - The Role of the Social Worker in MS
- The Role of the Social Worker in MS: Part I
Roberta Winter, MSW, LCSW, MSCS - The Role of the Social Worker As a Case Manager in MS
Andrea Dowdall, MSW, MEd - The Role of the Social Worker in MS: Part II
Roberta Winter, MSW, LCSW, MSCS - Domestic Violence - The Role of the Social Worker in MS
Sherie Lammers, REACH Director, Trainer, NMSS - Planning Ahead: Protecting Assets, Advance Directives, and Long-term Care
Dorothy E. Northrop, MSW, ACSW, Vice President - Research & Clinical Operations, NMSS
Book and Materials Review
|